Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


Articles published in Lancet Infect Dis

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    November 2017
  1. YERLY S, Calmy A
    Time to overcome pretreatment HIV drug resistance.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30709.
    PubMed     Text format    


  2. DORMAN SE, Schumacher SG, Alland D, Nabeta P, et al
    Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30691.
    PubMed     Text format     Abstract available


  3. GUPTA RK, Gregson J, Parkin N, Haile-Selassie H, et al
    HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30702.
    PubMed     Text format     Abstract available


  4. LIN C, Franceschi S, Clifford GM
    Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30653.
    PubMed     Text format     Abstract available


  5. HERMANS LE, Moorhouse M, Carmona S, Grobbee DE, et al
    Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30681.
    PubMed     Text format     Abstract available


  6. CASTAGNA A, Galli L
    Stepping up HIV-1 low-level viraemia surveillance in South Africa.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30680.
    PubMed     Text format    


  7. ZELENEV A, Li J, Mazhnaya A, Basu S, et al
    Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
    Lancet Infect Dis. 2017 Nov 15. pii: S1473-3099(17)30676.
    PubMed     Text format     Abstract available


  8. HILL AM, Venter F
    The unexpected success of NRTIs in second-line treatment.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30631.
    PubMed     Text format    


  9. HAKIM JG, Thompson J, Kityo C, Hoppe A, et al
    Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630.
    PubMed     Text format     Abstract available


  10. COUSINS S
    HIV and antenatal care in Sri Lanka: a global health success.
    Lancet Infect Dis. 2017;17:1126.
    PubMed     Text format    


    October 2017
  11. ABEL L, Fellay J, Haas DW, Schurr E, et al
    Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.
    Lancet Infect Dis. 2017 Oct 27. pii: S1473-3099(17)30623.
    PubMed     Text format     Abstract available


  12. FORD N, Ball A, Baggaley R, Vitoria M, et al
    The WHO public health approach to HIV treatment and care: looking back and looking ahead.
    Lancet Infect Dis. 2017 Oct 20. pii: S1473-3099(17)30482.
    PubMed     Text format     Abstract available


  13. CAMBIANO V, Miners A, Dunn D, McCormack S, et al
    Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30540.
    PubMed     Text format     Abstract available


  14. REVILL P, Dwyer E
    Pre-exposure prophylaxis is cost-effective for HIV in the UK.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30594.
    PubMed     Text format    


    September 2017
  15. BEIGEL JH, Bao Y, Beeler J, Manosuthi W, et al
    Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Lancet Infect Dis. 2017 Sep 22. pii: S1473-3099(17)30476.
    PubMed     Text format     Abstract available


  16. BAHR NC, Nuwagira E, Evans EE, Cresswell FV, et al
    Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.
    Lancet Infect Dis. 2017 Sep 14. pii: S1473-3099(17)30474.
    PubMed     Text format     Abstract available


    August 2017
  17. YOON C, Semitala FC, Atuhumuza E, Katende J, et al
    Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study.
    Lancet Infect Dis. 2017 Aug 25. pii: S1473-3099(17)30488.
    PubMed     Text format     Abstract available


  18. LOOKER KJ, Elmes JAR, Gottlieb SL, Schiffer JT, et al
    Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis.
    Lancet Infect Dis. 2017 Aug 23. pii: S1473-3099(17)30405.
    PubMed     Text format     Abstract available


  19. SALAM AP, Pozniak AL
    Disseminated aspergillosis in an HIV-positive cannabis user taking steroid treatment.
    Lancet Infect Dis. 2017;17:882.
    PubMed     Text format    


    July 2017
  20. COLOMBO AL, de Almeida Junior JN, Slavin MA, Chen SC, et al
    Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer.
    Lancet Infect Dis. 2017 Jul 31. pii: S1473-3099(17)30304.
    PubMed     Text format     Abstract available


  21. LIMPER AH, Adenis A, Le T, Harrison TS, et al
    Fungal infections in HIV/AIDS.
    Lancet Infect Dis. 2017 Jul 31. pii: S1473-3099(17)30303.
    PubMed     Text format     Abstract available


  22. ARMSTRONG-JAMES D, Brown GD, Netea MG, Zelante T, et al
    Immunotherapeutic approaches to treatment of fungal diseases.
    Lancet Infect Dis. 2017 Jul 31. pii: S1473-3099(17)30442.
    PubMed     Text format     Abstract available


  23. COLE DC, Govender NP, Chakrabarti A, Sacarlal J, et al
    Improvement of fungal disease identification and management: combined health systems and public health approaches.
    Lancet Infect Dis. 2017 Jul 31. pii: S1473-3099(17)30308.
    PubMed     Text format     Abstract available


  24. UNEMO M, Bradshaw CS, Hocking JS, de Vries HJC, et al
    Sexually transmitted infections: challenges ahead.
    Lancet Infect Dis. 2017 Jul 7. pii: S1473-3099(17)30310.
    PubMed     Text format     Abstract available


    June 2017
  25. HATCHER J, Williamson L
    Noma in a patient with HIV.
    Lancet Infect Dis. 2017;17:672.
    PubMed     Text format    


  26. BURKI T
    HIV in the Philippines.
    Lancet Infect Dis. 2017;17:589-590.
    PubMed     Text format    


    May 2017
  27. LOBUE PA, Mermin JH
    Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.
    Lancet Infect Dis. 2017 May 8. pii: S1473-3099(17)30248.
    PubMed     Text format     Abstract available


  28. RAJASINGHAM R, Smith RM, Park BJ, Jarvis JN, et al
    Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.
    Lancet Infect Dis. 2017 May 5. pii: S1473-3099(17)30243.
    PubMed     Text format     Abstract available


  29. GROOME MJ, Koen A, Fix A, Page N, et al
    Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2017 May 5. pii: S1473-3099(17)30242.
    PubMed     Text format     Abstract available


  30. BURKI T
    Claims of a cure for HIV come under fire.
    Lancet Infect Dis. 2017;17:484-485.
    PubMed     Text format    


    April 2017
  31. KIRBY T
    HIV vaccines: where are we now?
    Lancet Infect Dis. 2017;17:372-373.
    PubMed     Text format    


    March 2017
  32. SIMONI JM, Aunon FM, Kemp CG, Kutner BA, et al
    Implementation research on HIV adherence interventions: no time to wait.
    Lancet Infect Dis. 2017 Mar 2. pii: S1473-3099(17)30106.
    PubMed     Text format    


  33. DE BRUIN M, Oberje EJ, Viechtbauer W, Nobel HE, et al
    Effectiveness and cost-effectiveness of a nurse-delivered intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, open-label, randomised clinical trial.
    Lancet Infect Dis. 2017 Mar 2. pii: S1473-3099(16)30534.
    PubMed     Text format     Abstract available


  34. KECHICHIAN E, Tomb R
    Widespread borderline tuberculoid leprosy with HIV co-infection.
    Lancet Infect Dis. 2017;17:348.
    PubMed     Text format    


    February 2017
  35. KIRBY T
    Lynn Morris: the continuing quest for an HIV vaccine.
    Lancet Infect Dis. 2017;17:150.
    PubMed     Text format    


    January 2017
  36. CALLIGARO GL, Zijenah LS, Peter JG, Theron G, et al
    Effect of new tuberculosis diagnostic technologies on community-based intensified case finding: a multicentre randomised controlled trial.
    Lancet Infect Dis. 2017 Jan 4. pii: S1473-3099(16)30384.
    PubMed     Text format     Abstract available


  37. KIRBY T
    Jared Baeten-aiming to see off HIV.
    Lancet Infect Dis. 2017;17:35.
    PubMed     Text format    


  38. KIRBY T
    HIV pre-exposure prophylaxis: a tale of two countries.
    Lancet Infect Dis. 2017;17:32-33.
    PubMed     Text format    


  39. QUAIFE M, Terris-Prestholt F, Vickerman P
    The promise of multipurpose pregnancy, STI, and HIV prevention.
    Lancet Infect Dis. 2017;17:21-22.
    PubMed     Text format    


    December 2016
  40. JENKINS HE, Yuen CM, Rodriguez CA, Nathavitharana RR, et al
    Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis.
    Lancet Infect Dis. 2016 Dec 7. pii: S1473-3099(16)30474.
    PubMed     Text format     Abstract available


  41. BAGCCHI S
    Homophobic sentiment hinders Indonesia's anti-HIV drive.
    Lancet Infect Dis. 2016;16:1339.
    PubMed     Text format    


  42. OKANO JT, Blower S
    Sex-specific maps of HIV epidemics in sub-Saharan Africa.
    Lancet Infect Dis. 2016;16:1320-1322.
    PubMed     Text format    


    November 2016
  43. GREGSON J, Kaleebu P, Marconi VC, van Vuuren C, et al
    Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    Lancet Infect Dis. 2016 Nov 30. pii: S1473-3099(16)30469.
    PubMed     Text format     Abstract available


  44. LLIBRE JM
    Time to get serious with HIV-1 resistance in sub-Saharan Africa.
    Lancet Infect Dis. 2016 Nov 30. pii: S1473-3099(16)30447.
    PubMed     Text format    


  45. GOFF DA, Kullar R, Goldstein EJ, Gilchrist M, et al
    A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail.
    Lancet Infect Dis. 2016 Nov 17. pii: S1473-3099(16)30386.
    PubMed     Text format     Abstract available


  46. WAINBERG MA, Hull MW, Girard PM, Montaner JS, et al
    Achieving the 90-90-90 target: incentives for HIV testing.
    Lancet Infect Dis. 2016;16:1215-1216.
    PubMed     Text format    


    October 2016
  47. PETER T, Ellenberger D, Kim AA, Boeras D, et al
    Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring.
    Lancet Infect Dis. 2016 Oct 20. pii: S1473-3099(16)30212.
    PubMed     Text format     Abstract available


  48. RHEIN J, Nielsen K, Boulware DR, Meya DB, et al
    Sertraline for HIV-associated cryptococcal meningitis - Authors' reply.
    Lancet Infect Dis. 2016;16:1111-2.
    PubMed     Text format    


  49. VERINGA A, van der Elst KC, Day JN, Thwaites GE, et al
    Sertraline for HIV-associated cryptococcal meningitis.
    Lancet Infect Dis. 2016;16:1111.
    PubMed     Text format    


    September 2016
  50. NICHOLS BE, Boucher CA, van der Valk M, Rijnders BJ, et al
    Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Lancet Infect Dis. 2016 Sep 22. pii: S1473-3099(16)30311.
    PubMed     Text format     Abstract available


  51. NIESSEN L, Jaffar S
    Effective and efficient prevention of HIV infection.
    Lancet Infect Dis. 2016 Sep 22. pii: S1473-3099(16)30376.
    PubMed     Text format    


  52. DEGENHARDT L, Charlson F, Stanaway J, Larney S, et al
    Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013.
    Lancet Infect Dis. 2016 Sep 21. pii: S1473-3099(16)30325.
    PubMed     Text format     Abstract available


  53. NAYAGAM S, Thursz M, Sicuri E, Conteh L, et al
    Requirements for global elimination of hepatitis B: a modelling study.
    Lancet Infect Dis. 2016 Sep 13. pii: S1473-3099(16)30204.
    PubMed     Text format     Abstract available


    August 2016
  54. INZAULE SC, Ondoa P, Peter T, Mugyenyi PN, et al
    Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.
    Lancet Infect Dis. 2016 Aug 25. pii: S1473-3099(16)30118.
    PubMed     Text format     Abstract available


  55. ALSDURF H, Hill PC, Matteelli A, Getahun H, et al
    The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.
    Lancet Infect Dis. 2016 Aug 10. pii: S1473-3099(16)30216.
    PubMed     Text format     Abstract available


  56. MCCONNELL J
    The Lancet Infectious Diseases HIV Prevention Resource Center.
    Lancet Infect Dis. 2016 Aug 8. pii: S1473-3099(16)30310.
    PubMed     Text format     Abstract available


  57. SCRIVEN JE, Lalloo DG, Meintjes G
    Changing epidemiology of HIV-associated cryptococcosis in sub-Saharan Africa.
    Lancet Infect Dis. 2016;16:891-2.
    PubMed     Text format    


  58. FORD N, Vitoria M, Doherty M, Bertagnolio S, et al
    Tenofovir resistance and first-line antiretroviral therapy.
    Lancet Infect Dis. 2016;16:890-1.
    PubMed     Text format    


    July 2016
  59. BEESON JG, Fowkes FJ
    A malaria vaccine in children with HIV.
    Lancet Infect Dis. 2016 Jul 6. pii: S1473-3099(16)30209.
    PubMed     Text format    


  60. OTIENO L, Oneko M, Otieno W, Abuodha J, et al
    Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial.
    Lancet Infect Dis. 2016 Jul 6. pii: S1473-3099(16)30161.
    PubMed     Text format     Abstract available


  61. DE SOUZA CAMPOS FERNANDES RC, de Souza TL, Medina-Acosta E
    Congenital Zika syndrome in Brazil.
    Lancet Infect Dis. 2016;16:772.
    PubMed     Text format    


    June 2016
  62. ANSTEAD GM
    The centenary of the discovery of trench fever, an emerging infectious disease of World War 1.
    Lancet Infect Dis. 2016 Jun 30. pii: S1473-3099(16)30003.
    PubMed     Text format     Abstract available


  63. MCMULLAN BJ, Andresen D, Blyth CC, Avent ML, et al
    Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines.
    Lancet Infect Dis. 2016 Jun 16. pii: S1473-3099(16)30024.
    PubMed     Text format     Abstract available


    May 2016
  64. NEWELL ML, Iwuji C
    HIV treatment as prevention: applicable in sub-Saharan Africa?
    Lancet Infect Dis. 2016 May 9. pii: S1473-3099(16)30057.
    PubMed     Text format    


  65. OKANO JT, Robbins D, Palk L, Gerstoft J, et al
    Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men.
    Lancet Infect Dis. 2016 May 9. pii: S1473-3099(16)30022.
    PubMed     Text format     Abstract available


  66. VAN DE WIJER L, Schellekens AF, Burger DM, Homberg JR, et al
    Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.
    Lancet Infect Dis. 2016;16:e76-81.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: